Neoplasms

LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY

Retrieved on: 
Tuesday, August 3, 2021
Cancer, Lung cancer, Infectious causes of cancer, Neoplasms, Health, Treatment of cancer, Small-cell carcinoma

Pasadena, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) announced that its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer (SCLC) (Mirzapoiazova el al., Molecular Cancer Therapeutics, online July 12, 2021).

Key Points: 
  • A Pre-Clinical Study Reports that LB-100 Potentiates Standard Therapy for Small Cell Lung Cancer Providing a Strong Rationale for a Clinical Trial of LB-100 in Small Cell Lung Cancer Recently Initiated at City of Hope.
  • A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off.
  • The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml .

Familial Adenomatous Polyposis Epidemiology Forecast Research Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Cancer, Neoplasms, Clinical medicine, Gastrointestinal cancer, Hereditary cancers, Benign neoplasms, Familial adenomatous polyposis, Polyp, Oncology, Adenoma, FAP, Attenuated familial adenomatous polyposis

The "Familial Adenomatous Polyposis - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Familial Adenomatous Polyposis - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Familial Adenomatous Polyposis (FAP)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Familial Adenomatous Polyposis (FAP), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Familial Adenomatous Polyposis (FAP) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Familial Adenomatous Polyposis (FAP) epidemiology segmented as the Prevalent Cases of Familial Adenomatous Polyposis, Diagnosed cases of Familial Adenomatous Polyposis, Etiology-specific Prevalence of Familial Adenomatous Polyposis, Type-specific Prevalence of Familial Adenomatous Polyposis.

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
Friday, July 23, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Cancer, Neoplasms, Clinical medicine, Oncology, Anatomical pathology, Lung cancer, Epithelium, Squamous cell carcinoma, Carcinoma, Metástasis, Squamous cell skin cancer, Neuroendocrine carcinoma of the cervix, DecisionDx-SCC, Castle Biosciences, DECISIONDX-SCC, CASTLE BIOSCIENCES

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.

Key Points: 
  • DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.
  • The data further demonstrate that Castles DecisionDx-SCC test can provide clinicians with additional information on a patients metastatic risk to help them make more informed choices about their treatment and follow-up care.
  • All SCC tumor specimens were tested with DecisionDx-SCC and analyzed using Kaplan-Meier for metastasis-free survival (MFS) and Cox regression for risk of regional/distant metastasis.
  • DecisionDx-SCC is a 40-gene expression profile test that uses an individual patients tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.

Foresight Diagnostics’ PhasED-Seq Circulating Tumor DNA Platform Demonstrates Highly Sensitive Minimal Residual Disease (MRD) Detection in B-Cell Lymphomas

Retrieved on: 
Thursday, July 22, 2021
Clinical medicine, Medicine, Medical specialties, DNA, Oncology, Anatomical pathology, Circulating tumor DNA, Neoplasms, Liquid biopsy, Minimal residual disease, Biopsy, CAPP-Seq

AURORA, Colo., July 22, 2021 (GLOBE NEWSWIRE) -- Foresight Diagnostics today announced publication of studies demonstrating unprecedented analytical and clinical sensitivity of the Companys proprietary circulating tumor DNA (ctDNA) detection platform for minimal residual disease (MRD) detection in B-cell lymphomas.

Key Points: 
  • AURORA, Colo., July 22, 2021 (GLOBE NEWSWIRE) -- Foresight Diagnostics today announced publication of studies demonstrating unprecedented analytical and clinical sensitivity of the Companys proprietary circulating tumor DNA (ctDNA) detection platform for minimal residual disease (MRD) detection in B-cell lymphomas.
  • Physicians have recently begun using circulating tumor DNA (ctDNA) as a minimally invasive liquid biopsy approach to characterize cancers, particularly in the metastatic setting.
  • Superior MRD detection during treatment: PhasED-Seq was compared to SNV-based ctDNA detection in 88 DLBCL patients after 2 cycles of immuno-chemotherapy.
  • Accurate and rapid detection of residual disease at the completion of therapy presents a meaningful opportunity to intervene and improve outcomes.

Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors

Retrieved on: 
Wednesday, July 21, 2021
Cancer, Clinical medicine, Neoplasms, Carcinoma, Breast cancer, Triple-negative breast cancer, Transitional epithelium, Transitional cell carcinoma

Anti-TROP-2 coupled to SN38 (a DNA polymerase inhibitor) (ESG-401) has received approval to begin clinical trials.

Key Points: 
  • Anti-TROP-2 coupled to SN38 (a DNA polymerase inhibitor) (ESG-401) has received approval to begin clinical trials.
  • ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma.
  • ESG-401 potentially addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.

Immunomic’s Academic Collaborator Dr. John Sampson Recognized as “World Expert” in Glioblastoma as Part of Glioblastoma Awareness Day

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Mental health, Other Science, Research, Hospitals, Surgery, Science, Cancer, Health, Neoplasms, Oncology, Brain tumor, Glioblastoma, Blastoma

The publication recognized the top 0.1% of scholars writing about glioblastoma over the past ten years, a level they label as "World Expert.

Key Points: 
  • The publication recognized the top 0.1% of scholars writing about glioblastoma over the past ten years, a level they label as "World Expert.
  • Dr. Sampsons recognition as a World Expert in glioblastoma is part of Glioblastoma Awareness Day, which is being celebrated today, Wednesday, July 21, 2021.
  • This recognition is especially important today, on Glioblastoma Awareness Day, where we honor the patients, families, and care givers who have faced this complex and deadly type of brain cancer.
  • We look forward to continuing to collaborate with Dr. Sampson to advance our glioblastoma immunotherapy program, ITI-1000, through Phase 2 and toward patients in need.

Phoenix and Maricopa County Proclaim July 21st as Glioblastoma Awareness Day, Local Researchers Take One Step Closer to a Treatment

Retrieved on: 
Wednesday, July 21, 2021
Cancer, Brain tumor, Health, Neoplasms, Oncology, Glioblastoma, Blastoma

Glioblastoma is a currently untreatable form of cancer that kills more than 241,000 people around the world each year, including more than 10,000 Americans .

Key Points: 
  • Glioblastoma is a currently untreatable form of cancer that kills more than 241,000 people around the world each year, including more than 10,000 Americans .
  • "The declaration of Glioblastoma Awareness Day in Phoenix and Maricopa County is important because it helps us to make this disease more well-known."
  • Dr. Fonkem added, "The brain cancer community is working as hard as ever to take care of our patients with glioblastoma.
  • A resolution to declare Glioblastoma Awareness Day for July 21, 2021 passed the United States Senate by unanimous vote in May 2021.

Profound Medical to Release Second Quarter 2021 Financial Results on August 4 – Conference Call to Follow

Retrieved on: 
Thursday, July 15, 2021
Neoplasms, Sonalleve MR-HIFU, Uterine fibroid, Bone metastasis, Clinical medicine, Medicine, Medical ultrasonography, Surgical oncology

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Global Renal Cell Carcinoma Epidemiology and Patient Flow Report 2020-2035: Targeted Population for Research and Development, Commercialization - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Oncology, Kidney cancer, Medical specialties, Clinical medicine, Neoplasms, Renal cell carcinoma, Carcinoma, Kidney diseases, Rare diseases, Autosomal dominant disorders, Renal ultrasonography, Renal medullary carcinoma

The "Global Renal Cell Carcinoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Renal Cell Carcinoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Renal Cell Carcinoma Epidemiology and Patient Flow Analysis - 2021, provides Renal Cell Carcinoma epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Renal Cell Carcinoma patients, history of the disease at the population level (Renal Cell Carcinoma prevalence, Renal Cell Carcinoma incidence) and at the clinical level (from diagnosis to treated patients).
  • Renal Cell Carcinoma patient flow: Renal Cell Carcinoma prevalence, diagnosed, and drug-treated patients
    Demographics: Renal Cell Carcinoma patients by age group, gender
    The data from this research will help executives:
    Establish basis for Renal Cell Carcinoma market sizing, assessing market potential, and developing drug forecast models
    Identify Renal Cell Carcinoma patients segments through age groups, gender, and disease sub-types
    Evaluate Renal Cell Carcinoma market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005764/en/

Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Oncology, Cancer, Lung cancer, Infectious causes of cancer, Health, Neoplasms, Carcinoma, Cytopathology, Small-cell carcinoma, G1 Therapeutics

This "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape.

Key Points: 
  • This "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape.
  • "Extensive-Stage Small Cell Lung Cancer (ESCLC)- Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape is provided which includes the disease overview and Extensive-Stage Small Cell Lung Cancer (ESCLC) treatment guidelines.
  • Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.